MARKET

SNSS

SNSS

Sunesis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.890
+0.070
+2.48%
After Hours: 2.930 +0.04 +1.38% 19:34 01/15 EST
OPEN
2.740
PREV CLOSE
2.820
HIGH
2.950
LOW
2.670
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
11.30
52 WEEK LOW
1.120
MARKET CAP
52.29M
P/E (TTM)
-1.5564
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers - PNM, TNAV, SNSS, ZAGG, ELY
, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire - PRF · 12/30/2020 16:55
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers - PNM, TNAV, SNSS, ZAGG, ELY
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire · 12/30/2020 16:55
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR
, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire - PRF · 12/19/2020 21:55
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire · 12/19/2020 21:55
Microcaps mostly among premarket gainers
Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett
Seekingalpha · 12/15/2020 13:31
Sunesis rises 1.9% after Viracta sees registration trial in H1 for lymphoma regimen
Sunesis Pharmaceuticals (SNSS) gains 1.9% in early trading after Viracta Therapeutics, the company Sunesis has agreed to acquire, reports complete responses were observed across multiple  EBV+ lymphoma subtypes in a Phase 2 trial investigating an
Seekingalpha · 12/07/2020 14:36
Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA
, /PRNewswire/ -- Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV lymphomas.
PR Newswire - PRF · 12/07/2020 13:30
Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA
Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas.
PR Newswire · 12/07/2020 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNSS. Analyze the recent business situations of Sunesis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNSS stock price target is 3.250 with a high estimate of 5.00 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 10.90M
% Owned: 60.26%
Shares Outstanding: 18.09M
TypeInstitutionsShares
Increased
8
1.78M
New
20
-27.57K
Decreased
10
390.42K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Non-Executive Chairman
James Young
Chief Executive Officer
Parvinder Hyare
Executive Vice President
Adam Craig
Chief Accounting Officer/Vice President - Finance
Tina Gullotta
Director
Stephen Ketchum
Director
H. Ward Wolff
Independent Director
Steve Carchedi
Independent Director
Matthew Fust
Independent Director
Nicole Onetto
Independent Director
Homer Pearce
Independent Director
David Stump
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SNSS
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sunesis Pharmaceuticals, Inc. stock information, including NASDAQ:SNSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNSS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNSS stock methods without spending real money on the virtual paper trading platform.